Measuring therapeutic efficacy in patients with Alzheimer’s disease: role of instruments

peer-reviewed
Erstveröffentlichung
2011-04-07Autoren
Riepe, Matthias W.
Janetzky, Wolfgang
Lemming, Ole M.
Wissenschaftlicher Artikel
Erschienen in
Dementia and Geriatric Cognitive Disorders ; 31 (2011), 3. - S. 233-238. - ISSN 1420-8008. - eISSN 1421-9824
Link zur Originalveröffentlichung
https://dx.doi.org/10.1159/000326214Institutionen
UKU. Klinik für Psychiatrie und Psychotherapie IIExterne Kooperationen
Lundbeck GmbH PharmaunternehmenDokumentversion
Veröffentlichte Version (Verlags-PDF)Zusammenfassung
Background/Aims: Global cognitive scales and meta-analyses thereof are used to appraise therapeutic efficacy over a broad range of disease severity. Clinically, however, different aspects of cognition change in different stages of disease. Methods: Calculation of effect sizes for single cognitive functions on treatment as assessed by the Alzheimer’s Disease Assessment Scale (ADAS-cog), the Mini-Mental-Status Examination (MMSE), and the Severe Impairment Battery (SIB). In these scales, subdomains of ‘cognition’, e.g. memory and language, are represented in different proportions. To exemplify the analysis of ‘cognition’, we used original data of previously published clinical studies with memantine. Results: Depending on dementia severity and on the scale used, the effect size for memory varies between –0.44 and +0.34 and for language between –0.40 and +0.26. Conclusion: Beyond interstudy variance, effect sizes for treatment with antidementia drugs are subject to disease stage, instruments used, and interaction thereof. Therefore, clinical interpretation is necessary to appraise therapeutic efficacy in clinical studies and meta-analyses thereof when patients with different severity are included or different instruments are used. Alternatively, severity-adapted endpoints should be used for appraisal and meta-analysis of therapeutic efficacy. © In Copyright http://rightsstatements.org/vocab/InC/1.0/
Schlagwörter
[GND]: Alzheimerkrankheit | Therapie | Kognition | Metaanalyse[MeSH]: Alzheimer disease; Therapy | Cognition | Meta-analysis
[Freie Schlagwörter]: Effect size
Rechtevermerk
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.
Metadata
Zur LanganzeigeDOI & Zitiervorlage
Nutzen Sie bitte diesen Identifier für Zitate & Links: http://dx.doi.org/10.18725/OPARU-40131
Riepe, Matthias W.; Janetzky, Wolfgang; Lemming, Ole M. (2021): Measuring therapeutic efficacy in patients with Alzheimer’s disease: role of instruments. Open Access Repositorium der Universität Ulm und Technischen Hochschule Ulm. http://dx.doi.org/10.18725/OPARU-40131
Verschiedene Zitierstile >